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The ideally engineered bone should have similar structural and functional properties to the native tissue.
Although structural integrity is critical for functional bone regeneration, we know less about modulating the
structural properties of the engineered bone elicited by bone morphogenetic protein (BMP) than efficacy and
safety. Erythropoietin (Epo), a primary erythropoietic hormone, has been used to augment blood transfusion in
orthopedic surgery. However, the effects of Epo on bone regeneration are not well known. Here, we determined
the role of Epo in BMP2-induced bone regeneration using a cranial defect model. Epo administration improved
the quality of BMP2-induced bone and more closely resembled natural cranial bone with a higher bone volume
(BV) fraction and lower marrow fraction when compared with BMP2 treatment alone. Epo increased red blood
cells (RBCs) in peripheral blood and also increased hematopoietic and mesenchymal stem cell (MSC) popula-
tions in bone marrow. Consistent with our previous work, Epo increased osteoclastogenesis both in vitro and
in vivo. Results from a metatarsal organ culture assay suggested that Epo-promoted osteoclastogenesis con-
tributed to angiogenesis because angiogenesis was blunted when osteoclastogenesis was blocked by alendronate
(ALN) or osteoprotegerin (OPG). Earlier calcification of BMP2-induced temporary chondroid tissue was ob-
served in the Epo + BMP group compared to BMP2 alone. We conclude that Epo significantly enhanced the
outcomes of BMP2-induced cranial bone regeneration in part through its actions on osteoclastogenesis and
angiogenesis.
Introduction
The repair of large bone defects due to trauma, infection,or tumor resection remains a significant clinical chal-
lenge. As a promising alternative strategy to autografts, bone
morphogenetic protein (BMP) is often used for clinical bone
repair because of its unique osteogenic capability and rela-
tively straightforward handling properties. The dose of
BMP-2 or -7 required for spinal fusion or tibial fracture
nonunion is reported to be as high as 14 mg1–3 because of the
lower efficacy in humans compared to preclinical animal
studies.4 Considering the risks resulting from such high do-
ses of BMP,5,6 alternative technologies, such as gene thera-
py,7–10 polymer-based drug delivery,11,12 and multiple factor
release,13–15 have been developed to increase the osteogenic
capacity of BMP. Unfortunately, translating these intriguing
technologies into effective clinical therapeutics has been slow
because of their complexity and lingering safety concerns.
Therefore, it is desirable to develop a clinically applicable
approach to improve bone regeneration. In addition to effi-
cacy and safety, little attention has been paid to the quality of
the regenerated bone, including structure, biomechanics, and
the relationship to other marrow components.16 The quality
of the engineered bone is critical because it not only affects
biomechanical function, but it is also a key determinant for
its physiological roles and for adequate protection and sup-
port of the underlying tissues.16
Bone formation induced by BMPs develops through an
endochondral ossification process that includes mesenchy-
mal progenitor cell recruitment, condensation, and differ-
entiation into chondrocytes.17 This tissue subsequently
undergoes hypertrophy and is invaded by blood vessels,
osteoblasts, osteoclasts, and hematopoietic cells, and finally
bone and mature hematopoietic tissues are formed.18,19 The
newly formed bone is continuously modified by the natural
remodeling process that depends on resorption and for-
mation20 and this native remodeling process can also be
modified by physiological factors such as parathyroid
hormone.21 These findings support the development of new
strategies to modulate BMP2-engineered bone by admin-
istration of other physiological factors such as erythropoi-
etin (Epo).
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Epo is the principal hormone that stimulates red blood cell
(RBC) production in the marrow and has been widely used
for treatment of anemias caused by chronic kidney disease
and chemotherapy in cancer patients.22,23 Epo has also been
approved for use in patients undergoing orthopedic surgery
in the United States as a therapeutic alternative to blood
transfusions.24 However, the effects of Epo on bone regen-
eration are not well established.
It has long been suggested that there is a synergistic link
between bone formation and hematopoiesis. In support of
this concept is the observation that osteoblasts are required
for hematopoiesis and function along with endothelial si-
nusoids as a primary component of the hematopoietic stem
cell (HSC) niche.25,26 Conversely, it has been demonstrated
that HSCs directly support mesenchymal stem cell (MSC)
differentiation to osteoblasts.27 Further studies indicate that
Epo may couple bone formation and hematopoiesis by reg-
ulating the cell behavior of osteoblasts, osteoclasts, and
MSCs.28 Likewise, a dual role for osteoclasts in bone ho-
meostasis has recently been emphasized. Osteoclasts can not
only recruit MSCs to the site of bone remodeling29,30 but also
can stimulate bone formation29 while Epo can function to
stimulate osteoclastogenesis in vitro.28,31 Consequently, this
interdependent relationship between blood and bone lead
us to hypothesize that Epo may also function as a novel
physiological modulator of bone regeneration. Based on the
emerging roles of Epo in bone formation, we hypothesized
that Epo can serve as a physiological regulator to enhance
the outcome of BMP2-induced bone regeneration. We
therefore aimed to determine the role of Epo in bone tissue
engineering and the potential mechanisms by which Epo
regulates bone regeneration. Our ultimate goal is to develop
a clinically applicable approach to enhance the outcomes of
tissue-engineering-based bone regeneration.
Materials and Methods
Critical-sized cranial bone defect model
Care and use of the laboratory animals followed the
guidelines established by the University of Michigan Com-
mittee for the Use and Care of Animals. C57BL/6 mice (4–6
weeks; Harlan Laboratories) were used in all the animal
studies. Animals were anesthetized by intraperitoneal injec-
tion of ketamine (Hospira, Inc.) and xylazine, and bupre-
norphine (Reckitt Benckiser Pharmaceuticals, Inc.) was given
before and after the surgery as an analgesic. The skin over
the skull was shaved and prepared with a povidone-iodine
(Rite Aid, Corporation) scrub. A *0.7-cm full-thickness in-
cision was made and one 5-mm defect was created within
the parietal bone with a trephine bur. The periosteum was
completely cleared from the surface of the cranium by
scraping while the underlying dura mater was kept intact.
One microgram of recombinant human BMP2 (rhBMP2;
ProSpec-Tany Technogene Ltd.) was resuspended in 10 mL of
collagen I (BD Biosciences) and then incorporated into a
3.5 · 3.5 · 3.5 mm gelatin scaffold (Gelfoam; Pharmacia and
Upjohn). The BMP2/collagen/scaffolds or collagen/scaf-
folds were allowed to gel for 30 min at 37C before trans-
plantation into the defects. Sterile grafts were then placed
directly in the defects and the overlying tissue was closed
with surgical staples. Staples were removed 10 days after
surgery. Saline (0.9% sodium chloride; Hospira, Inc.) or
1000 U/mL Epo (EPOGEN; Amgen) was subcutaneously
injected into the defect area after implantation every other
day for up to 2 weeks. A total of 78 mice were used in our
animal experiments, and they were divided into four groups
and treated as follows. (1) Control group: the mice were
implanted with a collagen/scaffold and injected with saline;
four, four, five, and eight animals of which were euthanized
at 5, 7, 14, and 42 days after surgery, respectively. (2) Epo
group: the mice were implanted with a collagen/scaffold
and injected with Epo; four, five, four, and eight animals of
which were euthanized at 5, 7, 14, and 42 days after surgery,
respectively. (3) BMP2 group: the mice were implanted with
a BMP2/collagen/scaffold and injected with saline; four, six,
four, and eight animals of which were euthanized at 5, 7, 14,
and 42 days after surgery, respectively. (4) BMP2 + Epo
group: the mice were implanted with a BMP2/collagen/
scaffold and injected with Epo; four, six, four, and eight
animals of which were euthanized at 5, 7, 14, and 42 days
after surgery, respectively.
Microcomputed tomography three-dimensional
reconstruction and bone morphometry
The calvaria at 6 weeks were fixed for 2 days with Z-fix
(Anatech Ltd.) and then moved to 70% ethanol and scanned
at a voxel size of 18mm using a microcomputed tomography
(mCT) scanner (GE Healthcare Pre-Clinical Imaging). Micro
View software (GE Healthcare Pre-Clinical Imaging) was
used to generate a three-dimensional (3D) reconstruction
from the set of scans. A user-defined 3D contour was drawn
to include only the bone and inside marrow cavity within the
defined cylinder space. User-defined contours were drawn
every five images and interpolated for all images in between.
A fixed threshold (1000) was used to extract the mineralized
bone phase and the bone morphometry was calculated.
Histological analysis
The calvaria were fixed with Z-fix before histologic pro-
cessing at the University of Michigan School of Dentistry
histology core facility. Ten-micrometer sections were cut
from the middle of the scaffolds and stained with hematox-
ylin and eosin or Safranin O, for light microscopic observa-
tion. For immunohistochemistry detection, antigens in
rehydrated sections were retrieved in a pressure cooker for
15 min, incubated with anti-CD31 antibody (Abcam) at 1:100
dilutions at 37C for 2 h, and detected by an ImmPACT DAB
substrate kit (Vector Laboratories) using manufacturer’s in-
structions.
Peripheral blood analysis and flow cytometry
Peripheral blood was analyzed at the Unit for Laboratory
Animal Medicine pathology core facility of the University of
Michigan. Sca-1 + Lin-CD45 - and Sca-1 + Lin-CD45 - cells in
bone marrow were analyzed by a BD FACSAria flow
cytometer (BD Biosciences) as previously described.32 Brief-
ly, mononuclear cells were resuspended in Dulbecco’s
phosphate-buffered saline (Invitrogen) with 2% fetal bovine
serum (FBS; Invitrogen). The following murine antibodies
(BD Biosciences) were used to stain these cells: biotin-
conjugated rat anti-mouse Ly-6A/E (Sca-1) (clone E13-161.7),
anti-CD45R/B220-PE (clone RA3-6B2), anti-Gr-1-PE (clone
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RB6-8C5), anti-TCRab PE (clone H57-597), anti-TCRgz PE
(clone GL3), anti-CD11b PE (clone M1/70), and anti-Ter-119
PE (clone TER-119), and streptavidin-PE-Cy5 conjugate, anti-
CD45-APC-Cy7 (clone 30-F11).
Osteoclastogenesis in vitro and in vivo
Serum was collected from peripheral blood when the mice
were euthanized at 1 week (n = 4) and 2 weeks (n = 4). The levels
of tartrate-resistant acid phosphatase form 5b (TRAP-5b) in
serum were determined by a Mouse TRAP kit according to the
manufacturer’s instructions (Immunodiagnostic Systems, Inc.).
In vitro osteoclastogenesis was performed as previously de-
scribed.31 Briefly, whole bone marrow cells from one mouse
were seeded onto one 24-well plate. Cells were treated for 1
week with 20 U/mL recombinant human Epo and/or 10 ng/
mL rhBMP2 with medium containing 25 ng/mL recombinant
mouse receptor activator of nuclear factor ligand (RANKL;
PeproTech) and 25 ng/mL macrophage-colony stimulating
factor (PeproTech). Osteoclasts were evaluated by TRAP
staining (Sigma-Aldrich) according to the manufacturer’s in-
structions and the numbers of TRAP-positive multinucleated
cells (three or more nuclei per cell) were counted.
In vitro angiogenesis assay
The fetal mouse metatarsal angiogenesis assay was con-
ducted as described with modifications.33 Briefly, metatar-
sals were dissected from *17-day embryos (C57BL/6;
Harlan) and cultured in 24-well plates containing 150mL a-
minimum essential medium (Invitrogen) and 10% FBS (In-
vitrogen) for the first 3 days. The medium was replaced by
250 mL fresh medium containing vascular endothelial growth
factor (VEGF, 10 ng/mL; PeproTech), Epo (10 U/mL; Am-
gen), BMP2 (10 ng/mL; PeproTech), alendronate (10 nM,
ALN; Calbiochem), or osteoprotegerin (1mg/mL OPG; R&D
Systems, Inc.) on fourth day. Explants were cultured for
another 7 days and then fixed and stained for CD31. The
CD31-positive area was normalized to the bone area (n = 4–6).
Human umbilical vein endothelial cells (HUVECs; Invitrogen)
were used to study the direct effects of Epo on endothelial
cells. For proliferation assays, 5000 cells per well were plated
in 24-well plates and cultured in low serum growth supple-
ment (Invitrogen) containing the medium 200PRF (Invitro-
gen). The cells were stimulated with VEGF (10 ng/mL;
PeproTech) or Epo (10 or 20 U/mL; Amgen) for 2 days. The
relative cell number was measured by a colorimetric method
using a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)
2-(4-sulfonphenyl)-2H-tetrazolium compound (Cell-Titer 96
Aqueous One Solution Cell Proliferation Assay; Promega).
The endothelial tube formation assay was performed accord-
ing to the manufacturer’s instructions. Briefly, the HUVECs
were plated on Geltrex-coated 96-well plate at 5 · 104 cells
per well. The cells were cultured with Epo or VEGF over-
night and then fixed and stained with CellTracker Green
5-chloromethylfluorescein diacetate (Invitrogen).
Statistics and image editing
To test the significance of observed differences between
the study groups, a two-tailed homoscedastic t-test was ap-
plied. A value of p < 0.05 was considered to be statistically
significant. Values are reported as the mean – standard de-
viation. Brightness and contrast were adjusted equally across
all images for improved visibility.
Results
Epo improved BMP2-induced cranial
bone regeneration
Several important parameters of BMP2-induced bone
regeneration were significantly modulated by Epo adminis-
tration in a mouse critical-sized cranial defect model. Three-
dimensional images reconstructed from mCT data indicated
no significant bone formation in control and Epo-treated
groups, although a few small isolated bony islands were
observed in the middle of the defect area. In contrast, 1 mg of
BMP2 suspended in collagen/gelatin scaffolds resulted in
nearly complete healing of the 5-mm critical cranial defects in
both the BMP2 and BMP2 + Epo groups (Fig. 1A). The re-
generated tissue in the BMP2-treated group exhibited a
structure with a larger total volume (TV) and marrow cavity
compared with the BMP2 + Epo group (Fig. 1B). These vi-
sualized differences were quantified by mCT analysis where
the native calvarium from equivalent regions served as the
reference for the analysis (Table 1). The bone volume (BV)
fraction (BV/TV, 0.53 – 0.09%) of the BMP2-regenerated tis-
sue was significantly lower than the native calvarium
(0.92 – 0.05%), while the TV and BV were significantly
higher. The administration of Epo generated a significantly
higher BV fraction, lower TV, and similar BV compared to
the BMP2-treated group. Further, the trabecular bone thick-
ness in the combination group was also higher than the
BMP2 group, but lower than native bone. Histological ex-
amination indicated significantly more bone marrow in the
BMP2 group than in the BMP2 + Epo group (right panel of
Fig. 1B, C). The native calvarium had a typical lamellar
structure surrounding a sparsely populated marrow cavity.
No new bone or marrow tissue was observed in the defects
of the control and Epo-treated groups and were instead filled
with only fibrous connective tissue and residual collagen
scaffold (Fig. 1C). Significant bone and marrow tissue was
generated in both the BMP2- and BMP2 + Epo-treated
groups. Consistent with the mCT observation, the ratio of
bone area was significantly increased by Epo while the ratio
of marrow area was decreased by histological analyses (data
not shown). The total area of the bone and marrow was
decreased by Epo, although it was higher than the native
calvarial bone. Taken together, the in vivo data indicated that
Epo strongly augmented the structural properties and nature
of the marrow of the BMP2-generated bone.
Epo increased the stem cell pools in bone marrow
Epo administration increased both the hematopoietic and
mesenchymal progenitor cells in bone marrow. As expected,
erythropoiesis in peripheral blood was enhanced as early as
5 days post–Epo treatment. The erythropoietic response, in-
cluding hematocrit, RBC, and hemoglobin levels, was sig-
nificantly increased in the BMP2 + Epo group compared with
Epo group (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/tea). In line with
the expanded RBCs in peripheral blood, the size and weight
of spleens were increased by Epo administration (data not
shown). In addition to increased RBC numbers in peripheral
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blood, fluorescence-activated cell sorting analysis of multi-
lineage progenitor cells (Sca-1 + Lin - )34 in bone marrow was
also increased after Epo treatment (Fig. 2A). The majority of
the Sca-1 + Lin - cells were hematopoiesis-related cells that
were positive for CD45 and that were significantly increased
by Epo. Notably, Epo significantly increased the non-HSCs
(Sca-1 + Lin-CD45 - ). Further, the capacity of bone marrow
stromal cells to form colony forming units (CFU-F) was in-
creased by Epo treatment (Fig. 2B). Therefore, Epo admin-
istration was able to increase RBCs in peripheral blood and
also increase the hematopoietic and mesenchymal progenitor
cell populations in the bone marrow.
Epo increased osteoclastogenesis in vitro and in vivo
Considering the important role of osteoclasts in bone re-
modeling and regeneration, evidence for osteoclastogenesis
in all groups was examined by the serum TRAP-5b assay
(Fig. 3A). At 1 week, TRAP-5b was increased by both Epo
and BMP2. The highest level of TRAP-5b was observed in the
combined treatment group of BMP2 + Epo. After 2 weeks,
only the combined group demonstrated significantly greater
TRAP-5b levels compared to the control (scaffold only)
group, suggesting that Epo and BMP2 had synergistic effects
on ostoeclastogenesis (Fig. 3A). RANKL-induced osteoclas-
togenesis was elevated by Epo treatment in vitro (Fig. 3B).
However, BMP2 had limited effects on osteoclastogenesis
in vitro. That is, no synergistic effect was observed in vitro.
RANKL was essential for in vitro osteoclastogenesis as no
osteoclasts were induced in all the groups without RANKL
(data not shown). Therefore, the data demonstrated that Epo
treatment increased osteoclastogenesis in vitro and in vivo.
Epo increased angiogenesis
Angiogenesis was evaluated in vivo by counting the num-
ber of CD31 + blood vessels in the newly regenerated tissues.
More blood vessels were observed in regenerated tissues of
BMP2 + Epo-treated groups compared with the BMP2 group
at 1 week (Fig. 4A). No noticeable differences in blood vessel
number were observed between the BMP2 and BMP2 + Epo
groups at 2 weeks postsurgery (data not shown). The ability of
Epo to increase angiogenesis was confirmed using the fetal
mouse metatarsal assay in vitro (Fig. 4B). In contrast to Epo
treatment, or the combination of Epo and BMP2, BMP2 and
saline had no detectable effects on angiogenesis after 1 week of
treatment. However, to determine whether Epo could stimu-
late angiogenesis by directly targeting endothelial cells, the
FIG. 1. Epo improved BMP2-induced cranial bone regeneration. Different structures of regenerated bone were observed in
the BMP2 and BMP2 + Epo groups at 6 weeks. (A) Three-dimensionally reconstructed microcomputed tomography images of
cranial bone regeneration. (B) Low-magnification histological analysis of the whole cranial bone section. A larger total
volume and marrow cavity was observed in the BMP2 group compared with the BMP2 + Epo group. The black arrows
indicate the edges of the surgical defects. The scale bar represents 500mm. (C) High-magnification H&E-stained section from
the middle of the implants. The natural calvarium served as a reference. Improved bone fraction and decreased marrow
fraction of regenerated tissues were observed in the BMP2 + Epo group compared with the BMP2 group. The scale bar in (C)
represents 100mm. Representative data are shown (n = 8). Epo, erythropoietin; BMP, bone morphogenetic protein; H&E,
hematoxylin and eosin. Color images available online at www.liebertpub.com/tea
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proliferation and endothelial tube formation of HUVECs was
investigated. Epo and VEGF induced similar proliferation
rates of HUVECs (Fig. 4C, left panel), and also increased the
HUVEC tube formation by VEGF in vitro (Fig. 4C, right
panel). Interestingly, Epo-induced angiogenesis was largely
blunted when osteoclastogenesis was blocked by ALN or
OPG in the metatarsal organ culture assay (Fig. 4D). These
data suggested that osteoclastogenesis is essential for Epo-
mediated angiogenesis.
Epo promoted BMP2-induced endochondral
bone formation
To examine the role of Epo during early osteogenesis
in vivo, the cranial grafts were retrieved at 5, 7, and 14 days
after implantation (Fig. 5). By 5 days, the surrounding tissues
started migrating into the collagen scaffolds. Condensed
mesenchymal cells were found between the scaffold and
dura mater in the BMP2- and BMP2 + Epo-treated groups
(Fig. 5A). These cells stained positive with Safranin O (red
color) (Fig. 5B), a stain that identifies proteoglycans in car-
tilaginous matrix. The chondroid tissues were only observed
in the BMP2- and BMP2 + Epo-treated groups. This indicated
that BMP2 released from the scaffold was likely responsible
for progenitor cell recruitment and differentiation at an early
time point. At day 7, more tissue invaded the scaffolds in
all groups compared to earlier points. A thick chondroid-like
area between the scaffold and dura was observed in both
the BMP2- and BMP2 + Epo-treated groups. This chondroid
tissue was located exclusively on the dural side of the
FIG. 2. Epo increased stem
cell populations in vivo and
in vitro. (A) Stem cell
populations in bone marrow
were altered by Epo
administration.
Hematopoietic progenitor cell
(Sca-1 + Lin - CD45 + ) and
non-hematopoietic
progenitor cell (Sca-1 + Lin-
CD45 - ) numbers were both
elevated in bone marrow by
Epo at 2 weeks
posttreatment. (B) CFU-F of
whole bone marrow cells
in vitro. Whole bone marrow
cells were treated with Epo (5
and 10 U/mL) for 1 week and
then fixed and stained with
H&E. Epo significantly
increased the capability of the
CFU-F of the bone marrow
cells in vitro. Data are
presented as the mean – SD
(n = 4). CFU-F, colony
forming units; SD, standard
deviation.
Table 1. Erythropoietin Increases Bone Volume/Total Volume and Bone Mineral Density
(Microcomputed Tomography Analysis)
Natural crania BMP2 BMP2 + Epo p-Value
Total volume of ROI (mm3) 2.21 – 0.27 11.15 – 2.55 7.05 – 2.26 0.004
Volume of bone (mm3) 2.03 – 0.18 5.82 – 1.38 4.71 – 1.44 0.139
BMCs (mg) 1.47 – 0.28 3.37 – 0.86 3.07 – 1.13 0.556
BMD (mg/cc) 725.97 – 129.73 579.10 – 49.13 644.66 – 77.77 0.063
BV/TV 0.92 – 0.05 0.53 – 0.10 0.68 – 0.14 0.021
BS/BV 16.22 – 2.77 30.30 – 5.98 22.34 – 7.94 0.040
Tb.Th. 0.13 – 0.03 0.07 – 0.01 0.10 – 0.04 0.036
Tb.N. 7.43 – 1.00 7.75 – 0.93 7.23 – 1.52 0.424
Tb.Sp. 0.01 – 0.01 0.06 – 0.01 0.04 – 0.02 0.093
Data are mean – SD.
p-Value indicates BMP2 versus BMP2 + Epo group.
BMP, bone morphogenetic protein; EPO, erythropoietin; ROI, region of interest; BMCs, bone mineral contents; BMD, bone mineral density;
BV/TV, bone volume/total volume; BS/BV, bone surface/bone volume; Tb.Th., trabecular thickness; Tb.N., trabecular number; Tb.Sp.,
trabecular spacing.
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scaffold, which suggested that this tissue was mainly derived
from cells originating from the dura mater. Different features
of chondroid tissue were noticed between the BMP2- and
BMP2 + Epo-treated groups. Compared to the BMP2 group,
the BMP2 + Epo-treated groups exhibited more calcified areas
in the chondroid tissue as well as more blood vessel invasion
in the hypertrophic cartilage at the time points studied.
Moreover, the total Safranin O staining–positive area in each
sample was significantly greater in the BMP2 group than in
the BMP2 + Epo group. By 14 days, the chondroid tissues in
both BMP2 and BMP2 + Epo groups were completely replaced
by immature bone tissue (Fig. 5A, B).
Discussion
Despite understanding the function of Epo as a hemato-
poiesis-inducing hormone and our recognition of the close
functional relationship between blood and bone, the roles of
Epo in bone regeneration are not well appreciated or un-
derstood.35 Our current data indicate that Epo increases both
RBCs and their progenitor cells (Sca-1 + Lin - CD45 + ), and
the non-HSCs (Sca-1 + Lin - CD45 - ) (Fig. 2) that have been
characterized to be multipotent stem cell population in adult
tissues.32 Interestingly, this adult stem cell can be mobilized
and recruited to injured tissues.36,37 These observations,
coupled with previous reports, suggest that Epo increases
the stem cell pool in bone marrow and contributes to local
bone regeneration induced by BMPs.38,39
In line with the increase in hematopoietic-related pro-
genitor cells, Epo treatment increased the number of osteo-
clasts that are derived from the hematopoietic lineage (Fig.
3).35,40 This is a potentially important observation because
the mechanical integrity of the skeleton is maintained by
continuous bone remodeling, including bone formation by
osteoblasts and bone resorption by osteoclasts.20 Although
osteoclasts play an essential role in bone remodeling, their
contributions to bone tissue engineering have long been
overlooked.41 To mimic natural bone remodeling and repair,
the activity of osteoclasts would ideally be involved in the
engineering of bone. This participation by osteoclasts would
therefore potentiate the newly generated bone to be recog-
nized and integrated, and thus become a functional compo-
nent of the host bone.42,43
BMP2 has been shown to enhance osteoclastogenesis44,45
and serum TRAP levels were increased by BMP and Epo in
our in vivo studies (Fig. 3A). However, the effects of BMP2 on
osteoclastogenesis were only observed at 1 week and not at
2 weeks. This short-term effect is likely due to the rapid
diffusion and degradation of BMP2 after implantation. Our
in vitro data also suggest that a high dosage ( > 50 ng/mL) is
required for BMP2-enhanced osteoclastogenesis (Fig. 3B).
The repeated administration of Epo can therefore sustain
osteoclastogenesis followed by osteogenesis in BMP2-
induced generated tissues, which potentially contributes to
accelerating bone remodeling and improved structural
quality of the engineered bone.
FIG. 3. Epo increased osteoclastogenesis in vivo and in vitro. (A) TRAP-5b levels in serum at 1 and 2 weeks posttreatment.
TRAP-5b in serum was elevated by both BMP2 and Epo at 1 week. The combination of Epo and BMP2 showed the highest
osteoclastogenesis at 1 and 2 weeks. Data are presented as the mean – SD (n = 4). (B) Osteoclastogenesis of whole bone
marrow cells in vitro. Osteoclasts were stained with TRAP after 1 week of culture. RANKL-induced osteoclast numbers were
significantly increased by Epo treatment. BMP2 had limited effects on osteoclastogenesis even at high dosage (50 ng/mL).
Data are presented as the mean – SD (n = 4). TRAP-5b, tartrate-resistant acid phosphatase form 5b; RANKL, receptor activator
of nuclear factor ligand. Color images available online at www.liebertpub.com/tea
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The anabolic effects of Epo on vertebral bone formation
have also been observed in newborn and young mice (< 6
weeks).28 However, catabolic effects were recently reported in
long bones using 9-week-old mice.46 These findings suggest
that the effects of Epo may depend on the rates of native bone
formation. In developing bone, or BMP-induced regenerating
bone, Epo increases bone formation by increasing bone re-
modeling. In mature or old bone, Epo potentially increases
more bone resorption than bone formation. The dose of Epo in
our animal experiments was 1000 U/kg, which was based on
our preliminary data. In our previous work, Epo administra-
tion at 6000 U/kg via intraperitoneal injection for 4 weeks
significantly increased vertebral bone formation.28 To decrease
the potential side effects of the high dose of Epo, we used a
relatively low dose (1000 U/kg) and short duration (2 weeks)
in our current work. Similarly, we injected Epo directly into
the defect site to increase the local effects of Epo while
reducing its systemic hematopoietic response. As our data
indicated, the cranial bone regeneration was significantly
improved while the RBC numbers were moderately elevated.
FIG. 4. Epo stimulated angiogenesis in vivo and in vitro. (A) CD31 + blood vessels in regenerated tissues. Blood vessel
numbers were significantly higher in the BMP2 + Epo group than in the BMP2 group at 1 week. Representative data are
shown (n = 4). The scale bar represents 50mm. (B) Angiogenesis using fetal mouse metatarsal assay. Epo-stimulated angio-
genesis was detected using CD31 staining in vitro. The CD31-positive area was normalized to the bone area. Data are
presented as the mean – SD (n = 4–6). (C) The proliferation of HUVECs was strongly increased by Epo treatment. Data are
presented as the mean – SD (n = 4). Epo exhibited a less potent effect on tube formation of HUVECs compared with VEGF.
Representative data are shown (n = 4). (D) Epo-stimulated angiogenesis was blunted by ALN or OPG. Data are presented as
the mean – SD (n = 4–6). HUVECs, human umbilical vein endothelial cells; VEGF, vascular endothelial growth factor; ALN,
alendronate; OPG, osteoprotegerin. Color images available online at www.liebertpub.com/tea
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It was reported that Epo at a dose of 500 U/kg significantly
increased the fracture healing in a mouse femoral osteotomy
model.47 However, 300 U/kg and 10-day intraperitoneal in-
jection of Epo was found to decrease the trabecular BV in
mouse tibia.46 Therefore, the dosage, duration, and route for
Epo administration, and the anatomic site of bone to be
regenerated may also be important considerations for the
application of Epo for bone tissue engineering.
Consistent with angiogenesis being essential for bone
formation and regeneration,48–52 angiogenic factors, such as
VEGF, have been shown to improve BMP-induced bone re-
generation, and have proven to be an effective strategy in
preclinical bone tissue engineering studies.13–15,53 In view of
its direct stimulation of endothelial cells in vitro, Epo has been
recognized as an angiogenic factor for over 20 years.54,55 Much
later, Epo was reported to exhibit a nearly equivalent angio-
genic potential as VEGF in vitro.56 Moreover, the role of Epo in
angiogenesis was confirmed using gene knockout strategies
in mice.57 Angiogenesis was also demonstrated to be the
primary reason for the tissue-protective effect of Epo observed
in neurological and cardiovascular tissues.23 Recently, one
group reported Epo to improve long bone healing, possibly
due to its angiogenic effects.47,58,59 Despite these findings, the
role of Epo in bone repair remains largely unknown.
In this study, the Epo-induced increase in blood vessel
formation was also noticed in BMP2-induced cranial bone
regeneration as early as 1 week (Fig. 4A). It was noted that
FIG. 5. Epo stimulated BMP2-induced endochondral bone formation. (A) H&E-stained sections at 5, 7, and 14 days.
Chondroid-like tissues were found between the scaffold and dura mater in the BMP2- and BMP2 + Epo-treated groups as
early as 5 days. At day 7, more tissue invaded into the scaffolds in all groups compared to earlier points. Greater cartilage
area was observed in the BMP2 group compared with the BMP2 + Epo-treated groups. Epo treatment induced more calcified
areas in the chondroid tissue. At day 14, the chondroid tissues in both BMP2 and BMP2 + Epo groups were completely
replaced by immature bone tissues. (B) Safranin O–stained sections at 5, 7, and 14 days. The cartilage was confirmed by
Safranin O staining (red color). Similar pattern of the tissues in the regenerated area was observed. The scaffold, cartilage, and
bone tissues were pointed out with the arrows. The representative data were shown (n = 4–6). The scale bar represented
100 mm. Color images available online at www.liebertpub.com/tea
FIG. 6. Model of Epo’s action on BMP2-induced bone regen-
eration. Hematopoietic progenitor cell and MSC populations
were increased in bone marrow by Epo administration. The in-
creased hematopoietic progenitor cells may be responsible for
Epo-stimulated osteoclastogenesis. MSCs are expected to con-
tribute to the local bone regeneration. Osteoclasts are not only
essential for coupling bone formation and bone resorption, but
also important for Epo-stimulated angiogenesis. Angiogenesis is
required for the transition of BMP2-generated cartilage to bone.
Therefore, the structural properties of the BMP2-generated bone
are strongly augmented by Epo treatment. Epo is a pleiotropic
physiological factor in bone regeneration. The dashed area is the
region of bone regeneration. MSCs, mesenchymal stem cells.
Color images available online at www.liebertpub.com/tea
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the Epo-stimulated angiogenesis was blunted when osteo-
clastogenesis was inhibited by ALN or OPG (Fig. 4D). This
finding suggests that osteoclastogenesis is also important for
the Epo-mediated effects on angiogenesis. These data may
also explain why the more potent angiogenic effects of Epo
were observed in the metatarsal bone model (organ culture
including osteoclastogenesis) rather than in the endothelial
tube formation model (HUVECs without osteoclasts) and is
supported by the recent report on the novel role of osteo-
clasts for bone angiogenesis.33
Although Epo increased osteoclastogenesis and angio-
genesis and thus improved BMP2-induced bone regenera-
tion, the mechanism by which Epo changed the ratio of
BMP2-generated bone and marrow is not clear. Cranial bone
is normally repaired through the intramembranous bone
formation pathway, as it is in normal development. How-
ever, endochondral bone formation was observed in the
healing of critical-sized cranial defects elicited by exogenous
BMPs.48,60 The transient cartilagenous phase was replaced
by bone tissue and was mediated by angiogenesis.61 Carti-
lage formation was induced by BMP2 at 1 week in our ex-
periments (Fig. 5). The increased blood vessel invasion
and accompanied cartilage turnover were possibly induced
by Epo-mediated angiogenesis. Therefore, the duration of
BMP2-induced endochondral ossification was shortened
by Epo-elevated blood vessel invasion. Although the total
BMP2-regenerated BV was not changed by Epo, the volume
of marrow was significantly decreased by Epo because the
endochondral ossification was regarded as essential for bone
marrow formation.62
Our working model for the roles of Epo in BMP2-
induced bone regeneration is summarized in Figure 6. In
summary, Epo can significantly improve BMP2-induced
bone regeneration in critical-sized cranial bone defects.
Increased osteoclastogenesis and angiogenesis were stim-
ulated by Epo both in vitro and in vivo. Considering the
important roles of osteoclasts in bone remodeling, hema-
topoiesis, and angiogenesis, we hypothesize that osteo-
clastogenesis is the primary means for Epo-improved bone
regeneration. As a pleiotropic physiological factor, Epo
administration may be a clinically applicable approach to
promote bone regeneration.
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